5 powodów, dla których warto stosować solifenacynę Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
nietrzymanie moczu, pęcherz nadreaktywny, solifenacyna
##plugins.themes.bootstrap3.article.main##
Abstrakt
W pracy omówiono najciekawsze aspekty terapii nietrzymania moczu i pęcherza nadreaktywnego związane z zastosowaniem solifenacyny. Omówiono mechanizm jej działania, celowaną wybiórczość i wygodne dawkowanie. Podkreślono, iż terapia, szczególnie na tle konkurencyjnych substancji czynnych, znacząco redukuje ryzyko działań niepożądanych i poprawia jakość życia chorych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sapilak, B. J. (2024). 5 powodów, dla których warto stosować solifenacynę . Medycyna Faktów , 17(1(62), 67-71. https://doi.org/10.24292/01.MF.0124.10
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as worldwide problem. Int J Gynecol Obstet. 2003; 82: 327-38.
2. Przydacz M, Golabek T, Dudek P et al. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study. Sci Rep. 2020; 10(1): 19819.
3. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006; 4(1): 14-24. http://doi.org/10.1016/j.amjopharm.2006.03.004.
4. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93(3): 303-10.
5. Chapple CR, Cardozo L, Steers WD et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006; 60(8): 959-66.
6. Surkont G, Wlazlak E, Suzin J. Solifenacyna – pierwsze doświadczenia w leczeniu pęcherza nadreaktywnego. Przeg Menopauzalny. 2006; 1: 43-46.
7. Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmakol. 2002; 335: 97-103.
8. Olcucu MT, Teke K, Yildirim K et al. Comparison effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study. Int Braz J Urol. 2020; 46(2):185-93.
9. Shim M, Kim JK, Bang WJ et al. Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study. Investig Clin Urol. 2020; 61(6): 600-6.
10. Haab F, Cardozo L, Chapple C et al. Solifenacin Study Group. Longterm open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005; 47: 376-84.
11. Kelleher CJ, Cardozo L, Chapple CR et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005; 95(1): 81-5.
12. Eisen SA, Miller DK, Woodward RS et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150(9): 1881-4.
13. Cardozo L, Amarenco G, Pushkar D et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, doubl-blind trial of solifenacin (SUNRISE). BJU Int. 2013; 111(5): 804-10.
14. Lee KS, Choo MS, Seo JT et al. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS). Health Qual Life Outcomes. 2015; 13: 89.
15. Gomes CM, Averbeck MA, Kovama M et al. Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil. Urology. 2020; 4: 1403-15.
16. Ali MU, Fong KNK, Kannan P et al. Measures of quality of life of people with neurogenic overactive bladder: A systematic review of psychometric properties. EJOG 2024; 292: 40-57.
17. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011; 2011: 834753.
18. He W, Huang G, Cui W et al. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol. 2023; 49(5): 535-63.
2. Przydacz M, Golabek T, Dudek P et al. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study. Sci Rep. 2020; 10(1): 19819.
3. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006; 4(1): 14-24. http://doi.org/10.1016/j.amjopharm.2006.03.004.
4. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93(3): 303-10.
5. Chapple CR, Cardozo L, Steers WD et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006; 60(8): 959-66.
6. Surkont G, Wlazlak E, Suzin J. Solifenacyna – pierwsze doświadczenia w leczeniu pęcherza nadreaktywnego. Przeg Menopauzalny. 2006; 1: 43-46.
7. Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmakol. 2002; 335: 97-103.
8. Olcucu MT, Teke K, Yildirim K et al. Comparison effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study. Int Braz J Urol. 2020; 46(2):185-93.
9. Shim M, Kim JK, Bang WJ et al. Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study. Investig Clin Urol. 2020; 61(6): 600-6.
10. Haab F, Cardozo L, Chapple C et al. Solifenacin Study Group. Longterm open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005; 47: 376-84.
11. Kelleher CJ, Cardozo L, Chapple CR et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005; 95(1): 81-5.
12. Eisen SA, Miller DK, Woodward RS et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150(9): 1881-4.
13. Cardozo L, Amarenco G, Pushkar D et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, doubl-blind trial of solifenacin (SUNRISE). BJU Int. 2013; 111(5): 804-10.
14. Lee KS, Choo MS, Seo JT et al. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS). Health Qual Life Outcomes. 2015; 13: 89.
15. Gomes CM, Averbeck MA, Kovama M et al. Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil. Urology. 2020; 4: 1403-15.
16. Ali MU, Fong KNK, Kannan P et al. Measures of quality of life of people with neurogenic overactive bladder: A systematic review of psychometric properties. EJOG 2024; 292: 40-57.
17. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011; 2011: 834753.
18. He W, Huang G, Cui W et al. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol. 2023; 49(5): 535-63.